映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

交易中 05-20 10:35:15

225.200

+9.800

+4.55%

最高230.000	最低217.000	成交量61.62万
今开225.000	昨收215.400	日振幅6.04%
总市值203.64亿	流通市值203.64亿	总股本9,043万
成交额1.39亿	换手率0.68%	流通股本9,043万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":225.2,"timestamp":1779244515698,"preClose":215.4,"halted":0,"volume":616192,"delay":0,"changeRate":0.045496750232126196,"floatShares":90427800,"shares":90427800,"eps":-45.77728024065617,"marketStatus":"交易中","change":9.8,"latestTime":"05-20 10:35:15","open":225,"high":230,"low":217,"amount":138728495,"amplitude":0.060353,"askPrice":225.6,"askSize":1000,"bidPrice":225.2,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-36.65863004598476,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1779249600000},"marketStatusCode":2,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":215.4,"openAndCloseTimeList":[[1779240600000,1779249600000],[1779253200000,1779264000000]],"volumeRatio":2.295509,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606/","defaultTab":"news","newsList":[{"id":"2636899445","title":"映恩生物-B早盘涨近5% 拟回购最多4000万美元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636899445","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636899445?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:55","pubTimestamp":1779242100,"startTime":"0","endTime":"0","summary":"　　映恩生物-B盘中涨超6%，截至发稿，股价上涨4.83%，现报225.80港元，成交额9717.39万港元。　　5月19日，映恩生物-B发布公告，董事会拟行使公司股东于2025年6月 20日举行的股东周年大会上授予的一般授权项下的权力，于适当时机在公开市场购回公司股份。股份购回计划拟动用最多4000万美元购回股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-20/doc-inhypaet7044518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09606","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136251746","title":"异动解读｜映恩生物-B盘中上涨5.66%，行使DB-1311美国市场选择权后连续下挫迎来反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1136251746","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136251746?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:31","pubTimestamp":1779240703,"startTime":"0","endTime":"0","summary":"5月20日，映恩生物-B盘中上涨5.66%，报227.4港元，成交额794.67万港元。消息面上，公司此前于5月12日向BioNTech发出书面通知行使DB-1311/BNT324美国市场独家成本及利润/亏损分担选择权，股价自公告后连续多日下挫，从约257港元跌至5月19日的210.4港元，累计跌幅超18%。行使选择权后公司需向BioNTech支付其分担的过往开发成本，市场此前对公司短期资金压力的担忧有所缓解。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636852631","title":"映恩生物-B(09606)拟回购最多4000万美元股份 创始人朱忠远拟增持不超过500万美元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636852631","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636852631?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:10","pubTimestamp":1779199828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 公布，董事会拟行使公司股东于2025年6月 20日举行的股东周年大会上授予的一般授权项下的权力，于适当时机在公开市场购回公司股份。董事会认为，股份当前成交价未能反映其内在价值及公司业务前景，现为公司购回股份的良机。董事会认为，股份购回计划符合公司及其股东的整体最佳利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","HK0000500386.USD","BK1161","HK0000252152.HKD","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226906","title":"映恩生物-B(09606)：通知行使DB-1311/BNT324成本及利润╱亏损分担选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226906","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635226906?lang=zh_cn&edition=full","pubTime":"2026-05-13 06:35","pubTimestamp":1778625346,"startTime":"0","endTime":"0","summary":"公司有权于首款 DB-1311/BNT324产品的首次2期临床试验成功完成后的特定期限内随时行使该选择权。此举使公司能够根据合作协议的条款分担首款DB-1311/BNT324产品于美国的开发成本以及商业化利润与亏损。董事会认为，DB-1311/BNT324于多种肿瘤适应症已展现出令人鼓舞的临床数据，该产品于美国具有巨大商业潜力，行使DB-1311/BNT324成本及利润╱亏损分担选择权使公司能够把握DB-1311于美国的潜力，行使该选择权符合公司及其股东的整体最佳利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4566","LU2543165471.USD","BK4118","BK4588","HK0000252160.HKD","BK4552","BK1161","HK0000500386.USD","09606","BK4585","DB","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1130590785","title":"映恩生物-B4月股份变动月报披露，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1130590785","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130590785?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:52","pubTimestamp":1778151130,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年5月7日公布4月股份变动月报，报告期为截至2026年4月30日。公司注册股本维持为200,000,000股普通股，面值每股0.0001美元，总注册股本为20,000美元，较上月无变动。报告期内，公司普通股由90,238,014股增至90,427,814股，主要因首次公开发售前股权激励计划的行使事项新增发行189,800股普通股。月末公司并无任何库藏股，整体股本总数较上月小幅增加。公司确认已遵守香港联交所《上市规则》及相关法律规定，所有股份发行均经董事会正式授权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105900092","title":"映恩生物-B（09606）2025年ADC布局稳步拓展，收入18.52亿元、净亏损扩大至25.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105900092","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105900092?lang=zh_cn&edition=full","pubTime":"2026-04-26 19:24","pubTimestamp":1777202687,"startTime":"0","endTime":"0","summary":"映恩生物-B聚焦抗体-药物偶联物研发，为癌症及自身免疫疾病提供创新疗法。根据报告内容，公司已在高度竞争且快速发展的ADC领域布局多款候选药物，并通过持续投入研发强化产品管线。财务数据显示，2025年度公司收入为18.52亿元人民币，较2024年的19.41亿元下降4.6%。从资产负债状况来看，截至2025年12月31日，资产总额为38.93亿元人民币，较2024年末的20.90亿元增长86.2%，负债总额则降至14.66亿元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物-B（09606）2025年ADC布局稳步拓展，收入18.52亿元、净亏损扩大至25.95亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627261720","title":"中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627261720?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","LU0348827113.USD","HK0000500386.USD","LU0634319403.HKD","LU2778985437.USD","HK0000165453.HKD","01801","LU0502904849.HKD","LU0588546209.SGD","LU2543165471.USD","BK1588","LU2476274308.USD","06978","LU2399975544.HKD","09926","LU0417516738.SGD","LU2097828557.USD","01276","LU0417516902.SGD","06160","LU2097828805.USD","LU1719994722.HKD","LU2097828631.EUR","IE00B5MMRT66.SGD","BK1161","LU0196878994.USD","IE00B543WZ88.USD","LU0307460666.USD","LU0348825331.USD","HK0000252160.HKD","LU0561508036.HKD","09606","159992","LU0348783233.USD","LU0455707207.USD","LU2476274720.SGD","LU0540923850.HKD","LU0417516571.SGD","LU1770034418.SGD","LU1961090484.USD","LU2097828714.EUR","LU1794554557.SGD","LU2488822045.USD","LU0348784397.USD","LU0359202008.SGD","06990","LU0348766576.USD","LU1023057109.AUD","LU2328871848.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197788137","title":"异动解读 | 映恩生物-B盘中大涨5.02%，科创板上市计划提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1197788137","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197788137?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:33","pubTimestamp":1776216839,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，公司于盘前发布公告，董事会已批准发行人民币股份并在科创板上市的计划。公司拟发行不超过1577.92万股人民币股份，占发行后总股本的15%，募集资金将主要用于新药研发及补充营运资金。分析认为，A股市场对生物医药等硬科技赛道通常给予更高的流动性和估值溢价，映恩生物此次回A计划有望为公司带来价值重估。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478451","title":"加速全球ADC龙头价值构建，映恩生物-B(09606)推动“H+A”双资本平台布局释放长投信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478451","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627478451?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:00","pubTimestamp":1776211200,"startTime":"0","endTime":"0","summary":"4月13日晚，ADC龙头企业映恩生物-B发布公告宣布：董事会批准了发行人民币股份并在科创板上市的计划。对于映恩生物而言，自2025年6月成功实现港股上市后，此次拟申报科创板上市意味着公司正积极锚向“H+A”双资本平台布局，以进一步拓宽企业融资渠道、支持在研管线的临床推进及技术平台建设。作为全球ADC药物创新研发的前沿领导者之一，映恩生物的技术价值也获得了国际业界的高度认可。目前，双方联合用药的临床进展全球领先。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","BK4231","ADC","BK4080","LU2543165471.USD","HK0000500386.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627520451","title":"映恩生物-B(09606)拟发行人民币股份于科创板上市 募资不超过67.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627520451","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627520451?lang=zh_cn&edition=full","pubTime":"2026-04-13 22:46","pubTimestamp":1776091575,"startTime":"0","endTime":"0","summary":"映恩生物-B(09606)公布，于2026年4月13日，董事会批准于科创板建议人民币股份发行、特别授权及有关事项，须待股东于股东特别大会上批准及获得必要监管批准后，方可作实。 \n人民币股份发行募集资金总额预计将不超过人民币67.5亿元。扣除发行费用后，所得款项净额将全数用于与公司主营业务相关的项目。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["CYB","BK1161","MCNHmain","MUCmain","UCmain","HK0000252152.HKD","LU2543165471.USD","09606","CNHmain","IPOS","HK0000252160.HKD","HK0000500386.USD","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146987932","title":"映恩生物-B：人民币股份发行所得款项将用于创新药物研发等用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1146987932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146987932?lang=zh_cn&edition=full","pubTime":"2026-04-13 22:43","pubTimestamp":1776091393,"startTime":"0","endTime":"0","summary":"映恩生物-B宣布，其通过人民币股份发行筹集的资金，将主要用于支持公司创新药物的研发工作，以及其他相关业务发展。这一资金安排旨在进一步推动公司在生物医药领域的创新步伐，提升研发实力和市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09606","HK0000252152.HKD","BK1161","HK0000500386.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106054667","title":"映恩生物宣布抗HER2 ADC新药Trastuzumab Pamirtecan治疗晚期乳腺癌的BLA获中国国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1106054667","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106054667?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:58","pubTimestamp":1775735931,"startTime":"0","endTime":"0","summary":"映恩生物宣布，其针对不可切除或转移性HER2阳性成人乳腺癌的创新抗体偶联药物Trastuzumab Pamirtecan，已正式向中国国家药品监督管理局提交生物制品许可申请，并获受理。此次BLA获受理是基于一项关键性临床研究数据的积极结果。该研究旨在评估Trastuzumab Pamirtecan在经治的HER2阳性晚期乳腺癌患者中的疗效与安全性。若后续审评进展顺利并获得批准，Trastuzumab Pamirtecan将成为映恩生物在肿瘤治疗领域商业化进程中的重要里程碑，为国内HER2阳性乳腺癌患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","LU2543165471.USD","HK0000252152.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123067387","title":"国家药监局受理映恩生物DB-1303/BNT323治疗HER2阳性乳腺癌的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1123067387","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123067387?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:51","pubTimestamp":1775731872,"startTime":"0","endTime":"0","summary":"映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09606","LU2543165471.USD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626618686","title":"映恩生物-B(09606)：DB-1303/BNT323用于不可切除或转移性HER2阳性成人乳腺癌的新药上市申请获得国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2626618686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626618686?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:50","pubTimestamp":1775731855,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 发布公告，基于III 期关键临床研究所获得的积极结果和与国家药监局药品审评中心的新药上市申请前沟通交流反馈，提交的生物制品新药上市申请已获得国家药品监督管理局受理。DB-1303-O-3001试验是一项随机、对照、开放标签、多中心的III期临床试验，旨在评估DB-1303相较于T-DM1在既往接受曲妥珠单抗和紫杉烷类治疗的HER2 阳性不可切除或转移性乳腺癌患者中的疗效和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252152.HKD","BK4585","LU2543165471.USD","BK4552","BK4118","09606","BK4588","DB","IPOS","BK4566","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181868709","title":"映恩生物-B3月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1181868709","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181868709?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:41","pubTimestamp":1775731275,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。根据公告，公司本月注册股本仍为200,000,000股，面值USD 0.0001，注册股本金额维持20,000美元不变。报告期内，已发行股份由上月底的90,137,714股增至90,238,014股，新增发行股份共100,300股，均来自公司首次公开发售前股权激励计划的期权行使。公司当月无股份回购或注销活动，库存股份保持为零。截至本月末，公司已发行股份总数为90,238,014股，股本规模小幅增加。公告由联席公司秘书袁佳丽签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112073873","title":"异动解读 | 生物医药板块全线走高带动，映恩生物-B盘中大涨6.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112073873","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112073873?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:58","pubTimestamp":1774922310,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨6.11%，引起了市场的广泛关注。消息面上，港股生物医药股今日全线走高，映恩生物-B的上涨与板块整体强势表现密切相关。其中，昭衍新药在公布业绩后股价升逾14%，显著提振了市场对生物医药板块的情绪，进而带动了包括映恩生物-B、翰森制药、药明生物及药明康德在内的多只相关个股同步上涨。此次生物医药板块的普涨行情，反映了市场对该行业近期发展态势的关注与积极预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154463260","title":"异动解读 | 中金维持跑赢行业评级，映恩生物-B盘中大涨6.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154463260","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154463260?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:36","pubTimestamp":1774579011,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨6.41%，引起了市场的广泛关注。消息面上，中金公司发布研究报告，维持映恩生物-B“跑赢行业”评级，目标价430港元不变，较当前股价有63.4%的上行空间。报告指出，公司2025年收入达18.5亿元，超出该行预期，主要得益于研发合作报销收入超预期。此外，公司的核心管线全球开发进展顺利。公司与BioNTech的合作联用试验也预计将在2026年陆续取得数据，后续管线催化事件丰富。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622786816","title":"中金：维持映恩生物-B(09606)跑赢行业评级 目标价430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622786816?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:28","pubTimestamp":1774578495,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基于DCF模型，维持映恩生物-B跑赢行业评级和目标价430港元不变，较当前股价有63.4%的上行空间。中金主要观点如下：第一梯队管线全球开发全速推进根据公司公告，截至2025年，公司累计完成全球临床入组约3,200例患者，其中2025年新增入组约1,200人，约50%来自中国以外地区，体现高效执行力。公司DB-2304已经完成2a期试验的首例患者给药，建议关注自免ADC这一创新概念验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621170634","title":"映恩生物-B(09606)2025年实现收入约18.52亿元 管线开发与业务运营取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621170634","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621170634?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:53","pubTimestamp":1774270392,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 公布2025年业绩，收入约18.52亿元，毛利约5.89亿元，研究与开发开支约8.38亿元，同比增长0.12%。截至目前，该集团拥有10款处于临床阶段的ADC管线，并于全球的临床试验中入组逾3,200例患者。当中包括仅于2025年便迅速入组逾1,200例患者，其中约50%位于美国、欧盟、澳洲及中国境外其他地区。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B(09606)2025年实现收入约18.52亿元 管线开发与业务运营取得重大进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","BK1161","LU2543165471.USD","09606","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621705955","title":"映恩生物-B(09606)：花海清获委任为公司执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2621705955","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621705955?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:34","pubTimestamp":1774269248,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，自2026年3月23日起：(1)司文女士辞任公司执行董事及薪酬委员会成员;(2)花海清博士获委任为公司执行董事;(3)张韶壬先生获委任为公司首席财务官;(4)朱忠远博士获委任为公司薪酬委员会成员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","09606","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.1625},{"period":"1month","weight":-0.3065},{"period":"3month","weight":-0.372},{"period":"6month","weight":-0.3453},{"period":"1year","weight":0.1307},{"period":"ytd","weight":-0.2777}],"compareEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.1057},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}